Insmed (INSM) reported a Q1 net loss Thursday of $1.42 per diluted share, widening from a loss of $1.06 a year earlier.
Analysts polled by FactSet expected a loss of $1.34.
ARIKAYCE product revenue for the quarter ended March 31 was $92.8 million, up from $75.5 million a year earlier. ARIKAYCE is an inhaled antibiotic.
Analysts surveyed by FactSet expected $91.5 million.
For 2025, the biotech company continues to expect global ARIKAYCE product revenue of $405 million to $425 million. Analysts polled by FactSet expect $468.4 million.
Shares of the company were down aroun 0.04% in recent Thursday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。